|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: THOP1 |
Gene summary for THOP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | THOP1 | Gene ID | 7064 |
| Gene name | thimet oligopeptidase 1 | |
| Gene Alias | EP24.15 | |
| Cytomap | 19p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | P52888 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7064 | THOP1 | LZE7T | Human | Esophagus | ESCC | 8.86e-05 | 2.24e-01 | 0.0667 |
| 7064 | THOP1 | LZE24T | Human | Esophagus | ESCC | 2.50e-07 | 2.79e-01 | 0.0596 |
| 7064 | THOP1 | LZE21T | Human | Esophagus | ESCC | 4.52e-02 | 5.22e-01 | 0.0655 |
| 7064 | THOP1 | P1T-E | Human | Esophagus | ESCC | 6.80e-05 | 3.73e-01 | 0.0875 |
| 7064 | THOP1 | P2T-E | Human | Esophagus | ESCC | 3.69e-21 | 3.70e-01 | 0.1177 |
| 7064 | THOP1 | P4T-E | Human | Esophagus | ESCC | 1.49e-13 | 3.14e-01 | 0.1323 |
| 7064 | THOP1 | P5T-E | Human | Esophagus | ESCC | 8.40e-04 | 9.15e-02 | 0.1327 |
| 7064 | THOP1 | P8T-E | Human | Esophagus | ESCC | 1.90e-05 | 1.49e-01 | 0.0889 |
| 7064 | THOP1 | P9T-E | Human | Esophagus | ESCC | 2.11e-10 | 3.07e-01 | 0.1131 |
| 7064 | THOP1 | P10T-E | Human | Esophagus | ESCC | 7.98e-13 | 2.48e-01 | 0.116 |
| 7064 | THOP1 | P11T-E | Human | Esophagus | ESCC | 1.23e-06 | 2.83e-01 | 0.1426 |
| 7064 | THOP1 | P12T-E | Human | Esophagus | ESCC | 5.79e-16 | 2.77e-01 | 0.1122 |
| 7064 | THOP1 | P15T-E | Human | Esophagus | ESCC | 1.69e-06 | 2.16e-01 | 0.1149 |
| 7064 | THOP1 | P16T-E | Human | Esophagus | ESCC | 7.42e-11 | 2.05e-01 | 0.1153 |
| 7064 | THOP1 | P17T-E | Human | Esophagus | ESCC | 4.53e-09 | 4.57e-01 | 0.1278 |
| 7064 | THOP1 | P19T-E | Human | Esophagus | ESCC | 2.64e-03 | 5.20e-01 | 0.1662 |
| 7064 | THOP1 | P20T-E | Human | Esophagus | ESCC | 2.11e-06 | 1.95e-01 | 0.1124 |
| 7064 | THOP1 | P21T-E | Human | Esophagus | ESCC | 3.19e-23 | 3.94e-01 | 0.1617 |
| 7064 | THOP1 | P22T-E | Human | Esophagus | ESCC | 4.12e-11 | 2.12e-01 | 0.1236 |
| 7064 | THOP1 | P23T-E | Human | Esophagus | ESCC | 6.85e-10 | 2.85e-01 | 0.108 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000020917 | Esophagus | ESCC | protein polyubiquitination | 170/8552 | 236/18723 | 1.40e-16 | 1.09e-14 | 170 |
| GO:000020921 | Liver | HCC | protein polyubiquitination | 151/7958 | 236/18723 | 1.90e-11 | 7.59e-10 | 151 |
| GO:000020910 | Oral cavity | OSCC | protein polyubiquitination | 150/7305 | 236/18723 | 1.59e-14 | 9.27e-13 | 150 |
| GO:000020915 | Oral cavity | LP | protein polyubiquitination | 82/4623 | 236/18723 | 3.23e-04 | 3.26e-03 | 82 |
| GO:000020924 | Skin | cSCC | protein polyubiquitination | 103/4864 | 236/18723 | 2.57e-09 | 9.09e-08 | 103 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| THOP1 | SNV | Missense_Mutation | c.507N>C | p.Lys169Asn | p.K169N | P52888 | protein_coding | tolerated(0.08) | benign(0.125) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| THOP1 | SNV | Missense_Mutation | rs527473166 | c.1102N>A | p.Gly368Arg | p.G368R | P52888 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BH-A0E9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| THOP1 | SNV | Missense_Mutation | c.1784C>T | p.Pro595Leu | p.P595L | P52888 | protein_coding | tolerated(0.09) | benign(0.403) | TCGA-BH-A1EW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| THOP1 | insertion | In_Frame_Ins | novel | c.355_356insTGGGGTTTC | p.Tyr119delinsLeuGlyPheHis | p.Y119delinsLGFH | P52888 | protein_coding | TCGA-BH-A0E2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | ||
| THOP1 | insertion | In_Frame_Ins | novel | c.356_357insCCTTGTTGG | p.Tyr119_Gln120insLeuValGly | p.Y119_Q120insLVG | P52888 | protein_coding | TCGA-BH-A0E2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | ||
| THOP1 | SNV | Missense_Mutation | rs374219260 | c.200N>T | p.Ala67Val | p.A67V | P52888 | protein_coding | tolerated(0.24) | benign(0.019) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| THOP1 | SNV | Missense_Mutation | c.234N>C | p.Gln78His | p.Q78H | P52888 | protein_coding | deleterious(0.04) | benign(0.372) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| THOP1 | SNV | Missense_Mutation | novel | c.1405N>A | p.Glu469Lys | p.E469K | P52888 | protein_coding | tolerated(0.19) | benign(0.206) | TCGA-IR-A3LF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| THOP1 | SNV | Missense_Mutation | novel | c.1504N>A | p.Glu502Lys | p.E502K | P52888 | protein_coding | deleterious(0) | possibly_damaging(0.614) | TCGA-VS-A959-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| THOP1 | SNV | Missense_Mutation | rs199648840 | c.740N>A | p.Arg247Gln | p.R247Q | P52888 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 7064 | THOP1 | DRUGGABLE GENOME, PROTEASE | Karenitecin | KARENITECIN | ||
| 7064 | THOP1 | DRUGGABLE GENOME, PROTEASE | Icofungipen | ICOFUNGIPEN | ||
| 7064 | THOP1 | DRUGGABLE GENOME, PROTEASE | Nemonoxacin | NEMONOXACIN |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |